Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygens, Sammy, Oude Munnink, Bas, Gharbharan, Arvind, Koopmans, Marion, Rijnders, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384506/
https://www.ncbi.nlm.nih.gov/pubmed/35867699
http://dx.doi.org/10.1093/cid/ciac601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384506/
https://www.ncbi.nlm.nih.gov/pubmed/35867699
http://dx.doi.org/10.1093/cid/ciac601

Ejemplares similares